Inspire Investing LLC Decreases Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Inspire Investing LLC lessened its position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 7.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,243 shares of the company’s stock after selling 1,984 shares during the quarter. Inspire Investing LLC’s holdings in Deciphera Pharmaceuticals were worth $397,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at approximately $30,000. AJOVista LLC acquired a new position in shares of Deciphera Pharmaceuticals in the fourth quarter worth $76,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Deciphera Pharmaceuticals by 357.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,272 shares of the company’s stock worth $150,000 after purchasing an additional 7,246 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Deciphera Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after purchasing an additional 2,649 shares during the last quarter. Finally, Diversified Trust Co purchased a new stake in Deciphera Pharmaceuticals in the fourth quarter valued at $193,000. Hedge funds and other institutional investors own 70.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DCPH shares. Jonestrading reaffirmed a “hold” rating and issued a $25.60 target price on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Leerink Partnrs lowered shares of Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 29th. Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $9.00 to $26.00 in a research report on Tuesday, April 30th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $25.60 price objective (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Deciphera Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $24.17.

Deciphera Pharmaceuticals Stock Performance

NASDAQ:DCPH remained flat at $25.59 during trading hours on Tuesday. 600 shares of the company’s stock were exchanged, compared to its average volume of 1,292,551. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $25.61. The company’s 50-day moving average is $25.54 and its 200 day moving average is $19.34. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -11.58 and a beta of 0.19.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. The business had revenue of $45.00 million during the quarter, compared to analyst estimates of $45.99 million. Deciphera Pharmaceuticals had a negative net margin of 108.86% and a negative return on equity of 52.42%. On average, analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.15 EPS for the current fiscal year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.